Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept
A Single-arm, Multicenter Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Electromechanical Autoinjector to Self-inject Etanercept
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lincoln, NE
Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept
A Single-arm, Multicenter Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Electromechanical Autoinjector to Self-inject Etanercept
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept
A Single-arm, Multicenter Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Electromechanical Autoinjector to Self-inject Etanercept
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Orchard Park, NY
Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept
A Single-arm, Multicenter Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Electromechanical Autoinjector to Self-inject Etanercept
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Orchard Park, NY
Click here to add this to my saved trials
Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept
A Single-arm, Multicenter Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Electromechanical Autoinjector to Self-inject Etanercept
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Duncansville, PA
Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept
A Single-arm, Multicenter Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Electromechanical Autoinjector to Self-inject Etanercept
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Mesa, AZ
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Mesa, AZ
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Mesa, AZ
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Mesa, AZ
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Paradise Valley, AZ
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Paradise Valley, AZ
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Upland, CA
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Upland, CA
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Tamarac, FL
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Tamarac, FL
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Eagan, MN
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Eagan, MN
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Lincoln, NE
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Lincoln, NE
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Freehold, NJ
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Freehold, NJ
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Charlotte, NC
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Oklahoma City, OK
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Duncansville, PA
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Duncansville, PA
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Columbia, SC
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Columbia, SC
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Jackson, TN
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Jackson, TN
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Benbrook, TX
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Benbrook, TX
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Dallas, TX
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Dallas, TX
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Dallas, TX
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Houston, TX
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Houston, TX
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Houston, TX
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Mesquite, TX
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Mesquite, TX
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Seattle, WA
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Anniston, AL
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Anniston, AL
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Caba,
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Caba,
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Saint Louis, MO
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
League City, TX
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
League City, TX
Click here to add this to my saved trials
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigational Site
mi
from
Charleston, SC
Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis
A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Validation of the Short-term Antimicrobial Action of Transplanted Bacteria
Phase 1 Study of the Short-term Antimicrobial Action of Transplanted Bacteria in Adult Patients With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
UCSD Division of Dermatology
mi
from
San Diego, CA
Validation of the Short-term Antimicrobial Action of Transplanted Bacteria
Phase 1 Study of the Short-term Antimicrobial Action of Transplanted Bacteria in Adult Patients With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
UCSD Division of Dermatology
mi
from
San Diego, CA
Click here to add this to my saved trials
Examination of Whether Host Preconditioning Modifies Short-term Transplant Survival
Phase 1 Study of Whether Host Preconditioning Modifies Short-term Transplant Survival
Status: Enrolling
Updated:  12/31/1969
UCSD Division of Dermatology
mi
from
San Diego, CA
Examination of Whether Host Preconditioning Modifies Short-term Transplant Survival
Phase 1 Study of Whether Host Preconditioning Modifies Short-term Transplant Survival
Status: Enrolling
Updated: 12/31/1969
UCSD Division of Dermatology
mi
from
San Diego, CA
Click here to add this to my saved trials
The Immunological Basis for Treatment Resistance to Anti-TNF Treatments
The Immunological Basis for Treatment Resistance to Anti-TNF Treatments
Status: Enrolling
Updated:  12/31/1969
University of Michigan Department of Dermatology
mi
from
Ann Arbor, MI
The Immunological Basis for Treatment Resistance to Anti-TNF Treatments
The Immunological Basis for Treatment Resistance to Anti-TNF Treatments
Status: Enrolling
Updated: 12/31/1969
University of Michigan Department of Dermatology
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques
Evaluation of the Effect of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques
Status: Enrolling
Updated:  12/31/1969
UCSD Division of Dermatology
mi
from
San Diego, CA
Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques
Evaluation of the Effect of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques
Status: Enrolling
Updated: 12/31/1969
UCSD Division of Dermatology
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)
Status: Enrolling
Updated:  12/31/1969
Dermatology Research Associates
mi
from
Los Angeles, CA
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)
Status: Enrolling
Updated: 12/31/1969
Dermatology Research Associates
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)
Status: Enrolling
Updated:  12/31/1969
Tulane University School of Medicine: Dept. of Dermatology
mi
from
New Orleans, LA
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)
Status: Enrolling
Updated: 12/31/1969
Tulane University School of Medicine: Dept. of Dermatology
mi
from
New Orleans, LA
Click here to add this to my saved trials
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)
Status: Enrolling
Updated:  12/31/1969
Rockefeller University
mi
from
New York, NY
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)
Status: Enrolling
Updated: 12/31/1969
Rockefeller University
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)
Status: Enrolling
Updated:  12/31/1969
Wake Forest University
mi
from
Winston-Salem, NC
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)
Status: Enrolling
Updated: 12/31/1969
Wake Forest University
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)
Status: Enrolling
Updated:  12/31/1969
Case Western University
mi
from
Cleveland, OH
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)
Status: Enrolling
Updated: 12/31/1969
Case Western University
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)
Status: Enrolling
Updated:  12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)
Status: Enrolling
Updated: 12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)
Status: Enrolling
Updated:  12/31/1969
Kirk Barber Research
mi
from
Calgary,
Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris
Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)
Status: Enrolling
Updated: 12/31/1969
Kirk Barber Research
mi
from
Calgary,
Click here to add this to my saved trials
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Status: Enrolling
Updated:  12/31/1969
Rheumatology Associates, PC
mi
from
Birmingham, AL
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Status: Enrolling
Updated: 12/31/1969
Rheumatology Associates, PC
mi
from
Birmingham, AL
Click here to add this to my saved trials
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Status: Enrolling
Updated:  12/31/1969
Rheumatology Associates Of North Alabama, P.C.
mi
from
Huntsville, AL
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Status: Enrolling
Updated: 12/31/1969
Rheumatology Associates Of North Alabama, P.C.
mi
from
Huntsville, AL
Click here to add this to my saved trials
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Status: Enrolling
Updated:  12/31/1969
St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare
mi
from
Fullerton, CA
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Status: Enrolling
Updated: 12/31/1969
St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare
mi
from
Fullerton, CA
Click here to add this to my saved trials
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Status: Enrolling
Updated:  12/31/1969
Desert Medical Advances
mi
from
Palm Desert, CA
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Status: Enrolling
Updated: 12/31/1969
Desert Medical Advances
mi
from
Palm Desert, CA
Click here to add this to my saved trials
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Status: Enrolling
Updated:  12/31/1969
San Diego Arthritis Medical Clinic
mi
from
San Diego, CA
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Status: Enrolling
Updated: 12/31/1969
San Diego Arthritis Medical Clinic
mi
from
San Diego, CA
Click here to add this to my saved trials
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Status: Enrolling
Updated:  12/31/1969
Stanford Hospital and Clinics
mi
from
Stanford, CA
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Status: Enrolling
Updated: 12/31/1969
Stanford Hospital and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Status: Enrolling
Updated:  12/31/1969
Rheumatology Associates of Central Florida
mi
from
Orlando, FL
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Status: Enrolling
Updated: 12/31/1969
Rheumatology Associates of Central Florida
mi
from
Orlando, FL
Click here to add this to my saved trials
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Status: Enrolling
Updated:  12/31/1969
Millennium Research
mi
from
Ormond Beach, FL
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Status: Enrolling
Updated: 12/31/1969
Millennium Research
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Status: Enrolling
Updated:  12/31/1969
Integral Rheumatology & Immunology Specialists (IRIS)
mi
from
Plantation, FL
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
A LONG-TERM, OPEN-LABEL EXTENSION STUDY OF TOFACITINIB (CP-690,550) FOR THE TREATMENT OF PSORIATIC ARTHRITIS
Status: Enrolling
Updated: 12/31/1969
Integral Rheumatology & Immunology Specialists (IRIS)
mi
from
Plantation, FL
Click here to add this to my saved trials